Q-omics provides the consensus-scored CADM4 profile across patient tissues and cancer cell-line models. CADM4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CADM4 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CADM4 protein abundance shows 23,782 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where CADM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CADM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CADM4 survival associations across molecular data types. CADM4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CADM4 RNA expression–survival associations across cancer types. High CADM4 expression shows unfavorable associations in COAD and MESO, but favorable associations in HNSC, BLCA, KIRP and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CADM4 RNA expression.
This table summarizes CADM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CADM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CADM4 shows lower tumor expression in KIRC and higher tumor expression in LUSC, LUAD, UCEC, CHOL and LIHC. The KIRC box plot shows higher CADM4 RNA expression in normal versus tumor tissue (log2 FC = −2.275, t-test p < 0.001).
This table shows molecular features associated with CADM4 in patient tissues and cancer cell lines. In patient samples, CADM4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CADM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
